<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636322</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0147</org_study_id>
    <secondary_id>NCI-2016-00017</secondary_id>
    <secondary_id>2015-0147</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02636322</nct_id>
  </id_info>
  <brief_title>Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib</brief_title>
  <official_title>A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy for Patients With High Risk Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving rituximab, lenalidomide, and ibrutinib with
      chemotherapy works in treating patients with high-risk diffuse large B-cell lymphoma.
      High-risk large B-cell lymphoma is a type of cancer of the immune system that is usually
      fast-growing in the body. Monoclonal antibodies, such as rituximab, may block cancer growth
      in different ways by targeting certain cells. Ibrutinib may stop the growth of cancer cells
      by blocking some of the enzymes needed for cell growth. Biological therapies, such as
      lenalidomide, use substances made from living organisms that may stimulate or suppress the
      immune system in different ways and stop cancer cells from growing. Drugs used in
      chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and
      doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      Giving rituximab, ibrutinib, and lenalidomide with combination chemotherapy may kill more
      cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the overall response rate at the end of 2 cycles of therapy with rituximab,
      lenalidomide, and ibrutinib in patients with high risk newly diagnosed non-germinal center
      B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL).

      II. To determine the complete response rate at the end of 6 cycles of therapy with rituximab,
      lenalidomide, and ibrutinib combined with chemotherapy (cyclophosphamide, doxorubicin
      hydrochloride [hydroxydaunorubicin hydrochloride], vincristine sulfate [Oncovin], prednisone
      [CHOP] or etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, doxorubicin
      hydrochloride [hydroxydaunorubicin hydrochloride] [EPOCH]) in patients with high risk newly
      diagnosed non-GCB DLBCL.

      SECONDARY OBJECTIVES:

      I. To determine the overall response rate, landmark survival outcomes (progression free and
      overall survival), and safety of lenalidomide and ibrutinib with chemotherapy (CHOP or EPOCH)
      in patients with high risk newly diagnosed non-GCB DLBCL.

      II. To evaluate descriptively the complete response rate in rituximab, lenalidomide,
      ibrutinib (RLI)-CHOP and in RLI-EPOCH.

      EXPLORATORY OBJECTIVES:

      I. To evaluate the baseline and therapy induced changes in the profile of mutations, gene
      expression, minimal residual disease clonotype levels, immune cell subsets, and tumor protein
      expression in tumor biopsy and blood samples in patients with high risk newly diagnosed
      non-GCB DLBCL.

      OUTLINE:

      SMART START: Patients receive rituximab intravenously (IV) over 4-6 hours on day 1,
      lenalidomide orally (PO) once daily (QD) on days 1-10, and ibrutinib PO QD on days 1-21.
      Treatment repeats every 21 days for 2 cycles in the absence of disease progression or
      unacceptable toxicity.

      Patients are assigned to 1 of 2 arms.

      ARM I (RLI WITH EPOCH): After SMART START therapy, patients receive rituximab IV over 4-6
      hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients
      also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5,
      vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours
      on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days
      for 6 cycles in the absence of disease progression or unacceptable toxicity.

      ARM II (RLI WITH R-CHOP): After SMART START therapy, patients receive rituximab IV over 4-6
      hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients
      also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1,
      doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day
      1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year, and
      then every 4 months for another year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of rituximab, lenalidomide and ibrutinib alone defined as complete response or partial response</measure>
    <time_frame>Up to 6 weeks (2 cycles)</time_frame>
    <description>Overall response rate will be measured using Bayesian method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>At 18 weeks (6 cycles)</time_frame>
    <description>Complete response rate of rituximab, lenalidomide and ibrutinib with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone or etoposide, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride will be measured using Bayesian method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate at end of treatment in patients with adult diffuse large B-cell lymphoma</measure>
    <time_frame>1 year</time_frame>
    <description>Overall response rate will be measured using the Bayesian method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>Will be summarized by frequency and 95% confidence interval. The distribution of time-to-event endpoints will be estimated by Kaplan-Meier estimate. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>Will be summarized by frequency and 95% confidence interval. The distribution of time-to-event endpoints will be estimated by Kaplan-Meier estimate. Comparison of time-to-event endpoints by important subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>At 1 year</time_frame>
    <description>Complete response of rituximab, lenalidomide and ibrutinib with chemotherapy (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone or etoposide, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride rate will be measured using Bayesian method. Will be summarized by frequency and 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Toxicities will be summarized by grade and by their relationship to treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma Unclassifiable</condition>
  <arm_group>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>BTK Inhibitor PCI-32765</other_name>
    <other_name>CRA-032765</other_name>
    <other_name>Imbruvica</other_name>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (RLI WITH EPOCH)</arm_group_label>
    <arm_group_label>Arm II (RLI WITH R-CHOP)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed diagnosis of previously untreated DLBCL of the non-GCB
             DLBCL subtype

          -  No prior treatment except a prior limited-field radiotherapy, a short course of
             glucocorticoids =&lt; 25 mg daily of prednisone equivalent which must cease prior to day
             1 of cycle 1, and/or cyclophosphamide for an urgent lymphoma related problem at
             diagnosis (e.g. epidural cord compression, superior vena cava syndrome)

          -  Patient or durable power of attorney (DPA) for healthcare must be able to understand
             and voluntarily sign an Institutional Review Board (IRB) -approved informed consent
             form

          -  Patients must have bi-dimensional measurable disease, as defined as radiographically
             apparent disease with the longest dimension of &gt;= 1.5 cm

          -  Patients with performance status of =&lt; 3 (3 only allowed if decline in status is
             deemed related to lymphoma and felt potentially reversible by the treating physician)

          -  Serum bilirubin &lt; 1.5 x upper limit of normal (ULN) except in patients with Gilbert's
             syndrome as defined by &gt; 80% unconjugated bilirubin

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             ULN or &lt; 5 x ULN if hepatic metastases are present

          -  Absolute neutrophil count (ANC) &gt; 1000/mm^3 unless deemed related to lymphoma
             involvement in the bone marrow and felt potentially reversible by the treating
             physician

          -  Platelets &gt; 100,000/mm^3 unless deemed related to lymphoma involvement in the bone
             marrow and felt potentially reversible by the treating physician

          -  Renal function assessed by calculated creatinine clearance:

               -  Calculated creatinine clearance &gt;=30 ml/min by Cockcroft-Gault formula

          -  Patients must be willing to receive transfusions of blood products

          -  All study participants must be registered into the mandatory Revlimid Risk Evaluation
             and Mitigation Strategy (REMS) program, and be willing and able to comply with the
             requirements of the REMS program

          -  Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the
             scheduled pregnancy testing as required in the Revlimid REMS program

          -  Women of childbearing potential and men who are sexually active with a woman of
             childbearing potential must be practicing a highly effective method of birth control
             during and after the study (12 months for women and 3 months for men), consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in this clinical study; men must agree to not donate sperm during and
             for up to 3 months after their conclusion of therapy on study

          -  Able to take aspirin (81 mg) daily or alternative therapy as prophylactic
             anticoagulation

        Exclusion Criteria:

          -  Any serious medical condition including but not limited to uncontrolled hypertension,
             uncontrolled congestive heart failure within past 6 months prior to screening (class 3
             [moderate] or class 4 [severe] cardiac disease as defined by the New York Heart
             Association Functional Classification), uncontrolled diabetes mellitus,
             active/symptomatic coronary artery disease, chronic obstructive pulmonary disease
             (COPD), left ventricular ejection fraction (LVEF) less than 40%, renal failure, active
             infection, history of invasive fungal infection, moderate to severe hepatic disease
             (Child Pugh class B or C), active hemorrhage, laboratory abnormality, or psychiatric
             illness that, in the investigators opinion places the patient at unacceptable risk and
             would prevent the subject from signing the informed consent form; patients with
             history of cardiac arrhythmias should have cardiac evaluation and clearance

          -  Pregnant or lactating females

          -  Known hypersensitivity to lenalidomide or thalidomide, ibrutinib, rituximab,
             etoposide, vincristine, doxorubicin, cyclophosphamide, or prednisone

          -  Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B
             infection (not including patients with prior hepatitis B vaccination; or positive
             serum hepatitis B antibody); known hepatitis C infection is allowed as long as there
             is no active disease and is cleared by gastrointestinal (GI) consultation

          -  All patients with central nervous system involvement with lymphoma

          -  Diagnosis of prior malignancy within the past 2 years with the exception of
             successfully treated basal cell carcinoma, squamous cell carcinoma of the skin,
             carcinoma &quot;in situ&quot; of the cervix or breast; history of other malignancies are allowed
             if in remission (including prostate cancer patients in remission from radiation
             therapy, surgery or brachytherapy), not actively being treated, with a life expectancy
             &gt; 3 years

          -  Significant neuropathy (grades 2 or grade 1 with pain) within 14 days prior to
             enrollment

          -  Contraindication to any of the required concomitant drugs or supportive treatments or
             intolerance to hydration due to preexisting pulmonary or cardiac impairment including
             pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to
             lymphoma

          -  Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30
             days of study enrollment)

          -  Patients with severe bradycardia (heart rate &lt; 40 beats per minute [bpm], hypotension,
             light-headedness, syncope)

          -  Major surgery within 4 weeks of study entry, or wound that is not healed from prior
             surgery or trauma

          -  History of stroke or intracranial hemorrhage within 6 months prior to study entry

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists

          -  Requires chronic treatment with strong cytochrome P450, family 3, subfamily A (CYP3A)
             inhibitors

          -  Vaccinated with live, attenuated vaccines within 4 weeks of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Westin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

